Clinical Psychopharmacology and Neuroscience Papers in Press available online.

Effects of Long-Acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
jihoon Oh1, Jihae Oh1, Dong Wook Kim2, HyunChul You3, Sae Hoon Kim4, Soo In Kim5, In Won Chung6, Kuan Shu Wang7, Minah Kim8, Jong-Woo Paik9, Min Jung Koh10, Yoosun Lee10, Seok Young Choi10, Jung-Jin Kim 1,*
1Department of Psychiatry, Seoul St. Mary’s Hospital, The Catholic University of Korea, College of Medicine, 2Maumpyeonhan Mental Health Clinic, 3Department of Psychiatry, Soonchunhyang University Bucheon Hospital, 4Yangsan Hospital, 5Department of Psychiatry, Ewha Womans University College of Medicine, 6Institute of Spirituality and Mental Health, St. Andrew's Hospital, 7Department of Neuropsychiatry, Maryknoll General Hospital, 8Department of Neuropsychiatry, Seoul National University Hospital, 9Department of Psychiatry, Kyung Hee University College of Medicine, 10Medical Affairs, Janssen Korea
Objective: To investigate the effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social functioning of patients with schizophrenia
Methods: This study enrolled patients with schizophrenia receiving long-acting injectable 1-monthly paliperidone palmitate for at least 4 months and who subsequently received 3-monthly paliperidone palmitate. Accordingly, 418 patients were followed up for 24 weeks. Their clinical symptoms and social functioning were measured using the Clinical Global Impression-Severity of Illness and Personal and Social Performance scales.
Results: The Personal and Social Performance total score was significantly higher after 3-monthly paliperidone palmitate treatment than at baseline (baseline vs. week 24: 54.3 ± 18.0 vs. 61.0 ± 14.5 [mean ± s.d.]; P < 0.001; Wilcoxon signed-rank test); the proportion of patients in the mildly ill group (scores 71–100) also increased significantly (baseline vs. week 24: 16.5% vs. 20.6%; P < 0.001; McNemar-Bowker test). The mean Clinical Global Impression-Severity of Illness score decreased significantly (baseline vs. week 24: 3.7 ± 1.0 vs. 3.4 ± 0.9; P < 0.001; Wilcoxon signed-rank test), as did the proportion of patients in the severely ill group (baseline vs. week 24: 4.1% vs. 2.1%; P < 0.001; McNemar-Bowker test).
Conclusion: Continuous 3-monthly paliperidone palmitate treatment significantly enhances the personal and social performance of patients with schizophrenia and reduces the proportion of those with severe illness. These findings suggest that long-acting injectable antipsychotic administration at intervals longer than 1 month might improve the social functioning of and promote return to activities of daily living in patients with schizophrenia.
Accepted Manuscript [Submitted on 2021-08-30, Accepted on 2021-11-15]